This is a Reach announcement and the information contained is not considered to be material or to have a significant impact on management's expectations of the Company's performance. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.
4 October 2024
MicroSalt plc
("MicroSalt®" or the "Company")
Microsalt Announces Significant Expansion of Global Patent Portfolio
MicroSalt plc (AIM: SALT), a leading provider of full-flavour, natural salt with approximately 50% less sodium, is pleased to announce multiple developments in its patent portfolio worldwide.
The Company received a Certificate of Invention Patent in China for its patent application entitled "Improved Low Sodium Salt Compositions," now issued as Chinese Patent No. CN114206133.
In addition, on September 4, 2024, the Company received a Notice of Allowance in Mexico for its Mexican Patent Application No. MX2022001611, entitled "Improved Low Sodium Salt Composition." The Company anticipates a Mexican Patent to issue after payment of final issuance and initial annuity fees.
On August 19, 2024, the Australian Patent Office accepted the Company's Australian Patent Application No. AU2020326597, entitled "Improved Low Sodium Salt Composition," initiating a three-month opposition period. If the accepted application is not opposed, the Company anticipates an Australian patent to issue after the end of the three-month opposition period.
The Chinese Patent, allowed Mexican Patent Application, and accepted Australian patent application all claim priority to United States patent applications that issued as United States Patent No. 11,992,034, entitled "Low Sodium Salt Composition," and all are directed to a low sodium salt composition comprising salt adhered to a carrier particle produced according to a claimed process.
The Company has additional pending patent applications directed to its a low sodium salt composition comprising salt adhered to a carrier particle produced according to a claimed process in Canada, Hong Kong, Chile, Japan, Europe, Brazil, India, and Russia.
Rick Guiney, CEO of MicroSalt commented: "We are very pleased to witness the expansion of our intellectual property portfolio into some of the largest sodium markets in the world. We have made commercial inroads with customers in Asia, Europe and Australia and we see this development as very timely".
About MicroSalt plc
MicroSalt® is dedicated to innovating food technology solutions that enable people to live longer, healthier, and happier lives. Its patented low-sodium salt delivers natural salt with approximately 50% less sodium and may be used by both consumers and food manufacturers to decrease the amount of sodium in their food. SaltMe! chips are produced using MicroSalt®, a patented innovative salt technology which is 100% natural, non-GMO, gluten free, and Kosher certified, that does not contain any potassium chloride. To learn more about MicroSalt Inc. and MicroSalt® products, please visit https://microsalt.co, follow on X @microSaltPLC or contact:
MicroSalt plc | Via Flagstaff | |
Rick Guiney, CEO | | |
| | |
Flagstaff PR (Financial IR/FPR) | +44 (0)20 7129 1474 | |
Tim Thompson / Alison Allfrey / Anna Probert microsalt@flagstaffcomms.com | | |
Notes to Editors
MicroSalt® produces a patented full-flavour, low-sodium salt for food manufacturers and consumers.
MicroSalt is a major potential disruptor in the food market, thanks to its micron sized particles which deliver the same sense of saltiness to a wide range of foods but with approximately 50% less sodium. Excess sodium consumption is a significant contributor to cardiovascular disease and MicroSalt's solution meets the rising demand for healthier alternatives to traditional salt. The WHO has set a target for reducing global sodium intake by 30% by 2025, which it estimates will save 7 million lives by 2030.
Each year, cardiovascular disease costs the UK £19 billion - if the average salt intake was reduced by one gram per day, it has been estimated that 4,147 lives and £288 million would be saved each year in the UK. As a nation, the UK consumes 183 million kilograms of salt each year, and 70% of the typical person's sodium intake is hidden in processed foods.
Operational since 2018, MicroSalt uses a patent-protected technology which helps create high barriers to entry within the reduced-sodium salt market.
The Directors believe that MicroSalt is well positioned to capture growth in the low sodium market, which is expected to grow exponentially, and that there is also scope to enter the larger salt market.
ENDS
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.